These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8991237)

  • 21. Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria.
    Monath TP; Nasidi A
    Am J Trop Med Hyg; 1993 Feb; 48(2):274-99. PubMed ID: 8447531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A comparison of the serological effects of classical cholera vaccine and of purified fraction vaccine, with or without simultaneous yellow fever vaccine (author's transl)].
    Gateff C; Dodin A; Wiart J
    Ann Microbiol (Paris); 1975; 126(2):231-46. PubMed ID: 1098542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
    Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
    Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune responses to measles immunization and the impacts on HIV-infected children.
    Thaithumyanon P; Punnahitananda S; Thisyakorn U; Praisuwanna P; Ruxrungtham K
    Southeast Asian J Trop Med Public Health; 2000 Dec; 31(4):658-62. PubMed ID: 11414407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measles antibody levels from birth to 9 months of age in Nigerian infants.
    Abdurrahman MB; Greenwood BM; Olafimihan O; Whitle HC
    Afr J Med Med Sci; 1982 Sep; 11(3):113-5. PubMed ID: 6307026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine.
    Dumas R; Forrat R; Lang J; Farinelli T; Loutan L
    Adv Ther; 1997; 14(4):160-7. PubMed ID: 10174195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
    Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
    J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WHO-supported comparative studies of attenuated live measles virus vaccines.
    Cockburn WC; Pecenka J; Sundaresan T
    Bull World Health Organ; 1966; 34(2):223-31. PubMed ID: 4161187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The Expanded Programme on Immunization in 1988].
    Levy-bruhl D
    Dev Sante; 1989 Dec; (84):18-22. PubMed ID: 12282918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measles HI-antibody levels in Lagos children, Nigeria: a follow-up study to resurgence of measles in Lagos metropolis.
    Oyefolu AO; Omilabu SA
    West Afr J Med; 2001; 20(3):238-42. PubMed ID: 11922159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of yellow fever vaccine.
    Monath TP
    Dev Biol Stand; 1996; 87():219-25. PubMed ID: 8854020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
    Wong-Chew RM; Islas-Romero R; García-García Mde L; Beeler JA; Audet S; Santos-Preciado JI; Gans H; Lew-Yasukawa L; Maldonado YA; Arvin AM; Valdespino-Gómez JL
    Vaccine; 2006 Jan; 24(5):683-90. PubMed ID: 16154241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody response after measles immunization.
    Ariyasriwatana C; Kalayanarooj S; Pattamadilok S
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S701-6. PubMed ID: 14700170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.
    Nkrumah FK; Osei-Kwasi M; Dunyo SK; Koram KA; Afari EA
    Bull World Health Organ; 1998; 76(4):353-9. PubMed ID: 9803586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunologic response and post-vaccination reactions in children vaccinated against measles. I. Assessment of post-vaccination reactions].
    Naruszewicz-Lesiuk D; Kańtoch M; Polna I
    Przegl Epidemiol; 1974; 28(3):315-24. PubMed ID: 4471837
    [No Abstract]   [Full Text] [Related]  

  • 39. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
    Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
    Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.